Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
4D Molecular TherapeuticsFDMT 54 3-Year Book Growth Rate is 7.40% as of Jun. 2026, which is 85% above its 10-year median of 4.00. GuruFocus rates FDMT with a GF Score™ of 54/100 and a GF Value™ of $35.02 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,121 Biotechnology companies, 4D Molecular Therapeutics ranks better than 74.75% on this metric.
During the past 12 months, 4D Molecular Therapeutics's average Book Value per Share Growth Rate was -18.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 7.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -0.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of 4D Molecular Therapeutics was 7.40% per year. The lowest was -9.40% per year. And the median was 4.00% per year.
4D Molecular Therapeutics (NAS:FDMT) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
4D Molecular Therapeutics 3-Year Book Growth Rate Related Terms
FDMT vs ACHV, CLYM, NVCT: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, 4D Molecular Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's 3-Year Book Growth Rate falls into.
4D Molecular Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 7.40% mean?
4D Molecular Therapeutics (FDMT) has a 3-Year Book Growth Rate of 7.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for 4D Molecular Therapeutics and its competitors. This is 85% above median its historical median of 4.00. According to the industry distribution chart, 4D Molecular Therapeutics ranks #283 out of 1121 companies in the Biotechnology industry, placing it in the top 25.2%.
Is 4D Molecular Therapeutics' 3-Year Book Growth Rate too high?
4D Molecular Therapeutics' current 3-Year Book Growth Rate of 7.40% is 85% above median its 10-year median of 4.00. Based on the distribution chart, 4D Molecular Therapeutics ranks #283 out of 1121 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' 3-Year Book Growth Rate compare to ACHV and CLYM?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #283 out of 1121 companies for 3-Year Book Growth Rate. This puts 4D Molecular Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current 3-Year Book Growth Rate is 7.40%, which is 85% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $35.02, compared to a current price of $15.24 — trading 56.5% below its estimated fair value. The current 3-Year Book Growth Rate is 7.40%, which is 85% above median its 10-year median of 4.00. 4D Molecular Therapeutics' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current 3-Year Book Growth Rate is 7.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $15.24 is trading 56.5% below its estimated GF Value™ of $35.02.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
3-Year Book Growth Rate: 7.40% (85% above median its 10-year median of 4.00)
GF Value™: $35.02 vs. price of $15.24 (56.5% below fair value)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
54GF Score
Get the complete analysis for FDMT
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
